Treatment of pulmonary hypertension with leukotriene inhibitors

摘要

Pulmonary arterial hypertension (PAH) can be prevented in persons susceptible to the diseases and PAH patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene A4 hydrolase (LTA4H) inhibitors, leukotriene B4 receptor (BLT1/BLT2) antagonists, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxygenase activating protein (FLAP) inhibitors.

主权项

1. A method of treating pulmonary arterial hypertension in a subject in need thereof, said method comprising administering to said subject (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid or a pharmaceutically acceptable salt thereof at a daily dose of 100-200 mg/day, wherein the daily dose is administered on consecutive days for at least a month.